Portage Biotech
47 Avenue Road
Suite 200
Toronto
Ontario
M5R 2G3
Canada
Tel: 416-929-1806
Fax: 416-929-6612
Website: http://portagebiotech.com/
121 articles about Portage Biotech
-
Portage Biotech Announces Plans to Expand its Evaluation of Strategic Alternatives-Adenosine clinical development paused
4/12/2024
Portage Biotech Inc. today reported that it is expanding its evaluation of strategic alternatives and implementing additional measures to extend its available cash runway.
-
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
3/26/2024
Portage Biotech Inc. reported that it has completed selling its equity holding in Intensity Therapeutics.
-
Portage Biotech Reports Results for Fiscal Quarter Ended December 31, 2023, and Business Update
2/28/2024
Portage Biotech Inc., a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, reported financial results for the fiscal quarter ended December 31, 2023.
-
Portage Biotech Reports Business and Strategic Update
1/4/2024
Portage Biotech Inc. today announced the outcome from the company’s comprehensive review of its pipeline in the context of the current capital raising market conditions.
-
Portage Biotech Presents Updates on its iNKT and Adenosine programs at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
11/6/2023
Portage Biotech Inc. today announced the presentations of updates from its ongoing IMPORT-201 Phase 1/2 trial of PORT-2 (IMM60), an invariant natural killer T cell (iNKT) engager for patients with NSCLC and advanced melanoma, and its ADPORT-601 adaptive Phase 1a/1b trial for PORT-6 (A2A inhibitor) and PORT-7 (A2B inhibitor) in multiple solid tumors at SITC.
-
Portage Biotech Announces $6.0 Million Registered Direct Offering
9/29/2023
Portage Biotech Inc. announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of an aggregate of 3,157,895 shares of its common stock, at a purchase price of $1.90 per share.
-
Portage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
9/20/2023
Portage Biotech Inc. today announced that the Company’s management team will participate in a panel discussion at the Cantor Global Healthcare Conference on Thursday, September 28, 2023 at 10:20 – 10:50 AM ET in New York, NY.
-
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
9/5/2023
Portage Biotech Inc. today announced that it has entered into a clinical trial collaboration agreement with Merck to evaluate Portage’s next-generation adenosine antagonists in combination with KEYTRUDA ® (pembrolizumab).
-
Portage Biotech Reports Results for Fiscal Quarter Ended June 30, 2023 and Business Update
8/30/2023
Portage Biotech Inc. reported financial results for the fiscal quarter ended June 30, 2023.
-
Portage Biotech Reports Fiscal Year-Ended March 31, 2023 Financial Results and Business Update
7/31/2023
Portage Biotech Inc., a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, announced financial results for the fiscal year ended March 31, 2023.
-
Portage Biotech Announces First Patient Dosed in Phase 1a Trial of PORT-6 in Select Solid Tumors
6/26/2023
Portage Biotech Inc. announced today that it has dosed the first patient in its Phase 1a trial, ADPORT-601 ( NCT04969315 ).
-
Portage Biotech Reports Updated Interim Data for Lead iNKT Engager, PORT-2, in a Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
6/5/2023
Portage Biotech Inc. announced updated interim data from the Phase 1 portion of the trial evaluating its lead invariant natural killer T cell engager, PORT-2, alone and in combination with KEYTRUDA® in patients with advanced melanoma and metastatic non-small cell lung cancer presented in a poster presentation at the 2023 ASCO Annual Meeting.
-
Portage Biotech to Participate in Panel Discussion During the 2023 BIO International ConferenceIan Walters, M.D. to serve as expert panelist discussing the future of immune checkpoint inhibitors
6/1/2023
Portage Biotech Inc. announced that CEO Dr. Ian Walters will serve as an expert spokesperson on an oncology panel discussion at the upcoming BIO International Conference taking place in Boston, Massachusetts June 5-8, 2023.
-
Portage Biotech Announces Upcoming PORT-2 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
4/26/2023
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced the acceptance of a poster presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL.
-
Portage Biotech to Present at Oppenheimer’s 33rd Annual Healthcare Conference
3/7/2023
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will be presenting virtually at Oppenheimer’s 33rd Annual Healthcare Conference on March 13-15, 2023.
-
Portage Biotech Announces Results for Fiscal Quarter Ended December 31, 2022
3/1/2023
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced financial results for the fiscal quarter ended December 31, 2022.
-
Portage Biotech Hosting Key Opinion Leader Event on Targeting the Adenosine Pathway in Cancer
2/27/2023
Portage Biotech Inc. announced that it will host a key opinion leader webinar on targeting the adenosine pathway in cancer on Thursday, March 9, 2023 at 10:30 am Eastern Time.
-
Portage Biotech to Participate in Citi's 2023 Virtual Oncology Leadership Summit
2/15/2023
Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a fireside chat at Citi's 2023 Virtual Oncology Leadership Summit taking place on Febrarury 21 – 23, 2023.
-
JP Morgan week is shaping up to approximate pre-pandemic attendance levels as executives return to San Francisco after two years of COVID-19-enforced absences.
-
Portage Biotech Announces Results for Fiscal Quarter Ended September 30, 2022
11/29/2022
Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve patient lives and increase survival by avoiding and overcoming cancer treatment resistance, today announced financial results for the fiscal quarter ended September 30, 2022.